Ignite Creation Date:
2024-05-06 @ 3:29 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04659122
Status:
TERMINATED
Last Update Posted:
2023-08-14
First Post:
2020-12-04
Brief Title:
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
Sponsor:
Airway Therapeutics Inc
Organization:
Airway Therapeutics Inc
Study Overview
Official Title:
Phase 1b Open-label Single Arm Cohort Dose Escalation Study Evaluating the Safety Tolerability and Feasibility of Intervention With AT-100 rhSP-D in Intubated Patients Receiving Invasive Mechanical Ventilation With Severe COVID-19 Infection or Respiratory Failure Secondary to Severe Community Acquired Pneumonia
Status:
TERMINATED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Termination study goals reached
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if an investigational drug AT-100 is safe and tolerated by adults who have severe corona virus disease 2019 COVID-19 or respiratory failure secondary to severe community acquired pneumonia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None